Uric Acid Effects on Endothelium and Oxydative Stress
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03395977|
Recruitment Status : Recruiting
First Posted : January 10, 2018
Last Update Posted : January 12, 2018
Cardiovascular disease is the leading cause of mortality worldwide. Endothelial dysfunction (ED) is the main mechanism which leads to atherosclerosis, where the balance between pro and antioxidant factors results in a decreased nitric oxide (NO) bioavailability. Xanthine OxidoReductase (XOR) is one of the main generators of reactive oxygen species (ROS). Uric acid (UA), a major antioxidant in human plasma and end product of purine metabolism, is associated with cardiovascular diseases since many years; however the precise mechanisms which relate UA to ED are still not well understood.
The purpose of this study is to unravel the XOR and UA pathways involved in ED. Two groups of male participants (normo-uricemic and hyperucicemic) will be exposed to febuxostat (a strong and selective XOR inhibitor), or recombinant uricase (which oxidizes UA into allantoin) to vary UA levels and concomitantly control for confounding changes in XOR activity. Oxidative stress will be estimated by several markers. Endothelial function will be assessed by a laser Doppler imager in the presence of hyperthermia and endothelium stimulators. This study is specifically designed to untie the respective effects of UA and XOR pathways on oxidative stress and endothelial function in humans.
The investigators will test the following hypothesis:
- An extremely low level of uric acid after uricase administration induces endothelial dysfunction and oxydative stress,
- A specific XO inhibitor limits unfavourable effects of the serum UA reduction elicited by uricase administration,
- Endothelial function and oxydative stress are further improved with febuxostat as compared to placebo,
- All these observations are more marked in hyperuricemic subjects with a raised XO activity than in normouricemic subjects.
|Condition or disease||Intervention/treatment|
|Oxidative Stress Endothelial Function Cardiovascular System||Drug: Placebos Drug: Febuxostat Drug: Rasburicase|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||42 participants|
|Intervention Model:||Crossover Assignment|
|Intervention Model Description:||This is a prospective, randomized, placebo-controlled, double-blinded and 3 ways cross-over study. Two groups : normouricemic and hyperuricemic (21 participants in each group).|
|Masking:||Double (Participant, Investigator)|
|Masking Description:||Febuxostat and Rasburicase will be prepared by an independant pharmacist.|
|Primary Purpose:||Basic Science|
|Official Title:||Differential Effects of Uric Acid and Xanthine Oxidoreductase on Endothelial Function and Oxydative Stress|
|Actual Study Start Date :||January 3, 2018|
|Estimated Primary Completion Date :||December 31, 2019|
|Estimated Study Completion Date :||December 31, 2020|
Placebo Comparator: Placebos PO and IV
PO : per os IV : intraveinously
Lactose placebo for pills and saline for perfusion.
Experimental: Febuxostat PO and Placebo IV
240 mg a day for 3 days
Lactose placebo for pills and saline for perfusion.Drug: Febuxostat
Other Name: Adenuric
Experimental: Febuxostat PO And Rasburicase IV
Febuxostat : 240 mg a day for 3 days. Uricase : 3 mg once.
Other Name: AdenuricDrug: Rasburicase
Rasburicase injectable solution.
Other Name: Fasturtec
- Change in Oxydative stress biomarkers from baseline to 30 min or 24 hours after infusion of Uricase or Placebo [ Time Frame: Baseline, 30 minutes and 24 hours after infusion of Uricase or Placebo ]Among these oxidative stress biomarkers, we will measure F2 isoprostanes and malondialdehyde. F2-isoprostanes constitute the most reliable approach to assess oxidative stress in vivo. Malondialdehyde will be used as marker of cell injury. Due to their roles in the oxidative stress pathway, we will measure myeloperoxidase (MPO), protein-bound 3-chlorotyrosine and homocitrulline; MPO oxidized apolipoprotein A1, oxidized Trp72/Trp72 ratio and oxidized Met112/Met112 ratio; MPO-dependent modified LDL (Mox-LDL) ; angiotensin II (ANG II) and Interleukin-8 (IL-8). To assess the resolution of the oxidative stress and inflammation in vivo, we will measure the followed markers : resolvin D1, docosahexaenoic acid (DHA) and 17R-hydroxydocosahexaenoic acid (17-OHDHA). Superoxide production from cells incubated with plasma from participants. We will also measure blood and urinary allantoïn (the degradation product of uricase).
- Cutaneous perfusion by Laser Doppler (perfusion unit) [ Time Frame: 24 hours after infusion of Uricase or Placebo ]Perfusion unit (Laser Doppler Imager + iontophoresis of (ACh and SNP and hyperemia with ou without L-NAME). Assessment of endothelial function.
- Arterial stiffness [ Time Frame: 24 hours after infusion of Uricase or Placebo ]Carotido-femoral pulse wave velocity and pulse wave analysis
- Blood pressure (mmHg) [ Time Frame: 24 hours after infusion of Uricase or Placebo ]Beat-to-beat measurements with Finapres
- Cardiac output (l-min) [ Time Frame: 24 hours after infusion of Uricase or Placebo ]Beat-to-beat measurements with Finapres
- Change in enzymes activity [ Time Frame: 30 min and 24 hours after infusion of Uricase or Placebo ]Xanthin oxydase activity
- Change in enzymes expression [ Time Frame: 30 min and 24 hours after infusion of Uricase or Placebo ]eNOS, NOX, XO we will incubate endothelial cells with plasma or serum from subjects. Then we will measure the sus-mentionned enzymes' expression.
- Change in proteomic analysis [ Time Frame: 30 min and 24 hours after infusion of Uricase or Placebo ]We will perform proteomics analysis directly on serum from participants and also on lysate of endothelial cells pre-incubated with plasma or serum from participants.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03395977
|Contact: Benjamin De Becker||+32474328542||Benjamin.De.Becker@erasme.ulb.ac.be|
|Brussels, Belgique, Belgium, 1070|
|Contact: Benjamin De Becker +32474328542 Benjamin.De.Becker@erasme.ulb.ac.be|
|Principal Investigator: Benjamin De Becker|
|Study Director:||Philippe van de Borne||Erasme Hospital|